US Pharma MarketingAstraZeneca shares slump after $400bn BMS merger rumours
AstraZeneca shares slump after $400bn BMS merger rumours is a pharma and life sciences industry update from Pharmaceutical Technology. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
One of the largest global pharma companies would be created if a deal were to materialise.
Source: Pharmaceutical Technology